Muscular Dystrophy - Pipeline Review, H1 2018

  • ID: 4537891
  • Report
  • 152 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • Benitec Biopharma Ltd
  • Corcept Therapeutics Inc
  • Genethon SA
  • Pfizer Inc
  • SanBio Inc
  • MORE
Muscular Dystrophy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H1 2018, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights:

This latest pipeline guide Muscular Dystrophy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 2, 1, 29 and 14 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 6 molecules, respectively.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • Benitec Biopharma Ltd
  • Corcept Therapeutics Inc
  • Genethon SA
  • Pfizer Inc
  • SanBio Inc
  • MORE
Introduction

Muscular Dystrophy - Overview

Muscular Dystrophy - Therapeutics Development

Muscular Dystrophy - Therapeutics Assessment

Muscular Dystrophy - Companies Involved in Therapeutics Development

Muscular Dystrophy - Drug Profiles

Muscular Dystrophy - Dormant Projects

Muscular Dystrophy - Discontinued Products

Muscular Dystrophy - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Muscular Dystrophy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Muscular Dystrophy - Pipeline by Acceleron Pharma Inc, H1 2018

Muscular Dystrophy - Pipeline by Achelios Therapeutics Inc, H1 2018

Muscular Dystrophy - Pipeline by AMO Pharma Ltd, H1 2018

Muscular Dystrophy - Pipeline by Benitec Biopharma Ltd, H1 2018

Muscular Dystrophy - Pipeline by Bio Blast Pharma Ltd, H1 2018

Muscular Dystrophy - Pipeline by Biophytis SA, H1 2018

Muscular Dystrophy - Pipeline by Corcept Therapeutics Inc, H1 2018

Muscular Dystrophy - Pipeline by Evotec AG, H1 2018

Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H1 2018

Muscular Dystrophy - Pipeline by Genethon SA, H1 2018

Muscular Dystrophy - Pipeline by Gilead Sciences Inc, H1 2018

Muscular Dystrophy - Pipeline by Marina Biotech Inc, H1 2018

Muscular Dystrophy - Pipeline by Pfizer Inc, H1 2018

Muscular Dystrophy - Pipeline by Prothelia Inc, H1 2018

Muscular Dystrophy - Pipeline by Recursion Pharmaceuticals Inc, H1 2018

Muscular Dystrophy - Pipeline by Resverlogix Corp, H1 2018

Muscular Dystrophy - Pipeline by SanBio Inc, H1 2018

Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2018

Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H1 2018

Muscular Dystrophy - Pipeline by Strykagen Corp, H1 2018

Muscular Dystrophy - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2018

Muscular Dystrophy - Dormant Projects, H1 2018

Muscular Dystrophy - Dormant Projects, H1 2018 (Contd..1), H1 2018

Muscular Dystrophy - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Muscular Dystrophy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acceleron Pharma Inc
  • Achelios Therapeutics Inc
  • AMO Pharma Ltd
  • Benitec Biopharma Ltd
  • Bio Blast Pharma Ltd
  • Biophytis SA
  • Corcept Therapeutics Inc
  • Evotec AG
  • Fulcrum Therapeutics Inc
  • Genethon SA
  • Gilead Sciences Inc
  • Marina Biotech Inc
  • Pfizer Inc
  • Prothelia Inc
  • Recursion Pharmaceuticals Inc
  • Resverlogix Corp
  • SanBio Inc
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics Inc
  • Strykagen Corp
  • Ultragenyx Pharmaceutical Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll